{
  "ticker": "EXEL",
  "company_name": "Exelixis",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02036476",
      "title": "Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Merkel Cell Carcinoma, Skin Cancer",
      "start_date": "2014-02",
      "completion_date": "2016-07",
      "enrollment": 0,
      "sponsor": "Dana-Farber Cancer Institute"
    },
    {
      "nct_id": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Renal Cell Carcinoma",
      "start_date": "2025-11-26",
      "completion_date": "2032-02-27",
      "enrollment": 0,
      "sponsor": "Merck Sharp & Dohme LLC"
    },
    {
      "nct_id": "NCT04220229",
      "title": "Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities",
      "start_date": "2020-06-01",
      "completion_date": "2024-10-31",
      "enrollment": 0,
      "sponsor": "University of Washington"
    },
    {
      "nct_id": "NCT01657591",
      "title": "Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Melanoma",
      "start_date": "2012-07-27",
      "completion_date": "2021-09-21",
      "enrollment": 0,
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute"
    },
    {
      "nct_id": "NCT03213626",
      "title": "Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Pancreatic Adenocarcinoma Metastatic",
      "start_date": "2017-10-13",
      "completion_date": "2019-11-18",
      "enrollment": 0,
      "sponsor": "Patrick Joseph Loehrer Sr."
    },
    {
      "nct_id": "NCT03299946",
      "title": "Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Locally Advanced Hepatocellular Carcinoma",
      "start_date": "2018-05-14",
      "completion_date": "2021-10-01",
      "enrollment": 0,
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
    },
    {
      "nct_id": "NCT00350831",
      "title": "Study of XL820 Given Orally Daily to Subjects With Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Cancer",
      "start_date": "2006-07",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Exelixis"
    },
    {
      "nct_id": "NCT01522443",
      "title": "Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms",
      "start_date": "2012-03",
      "completion_date": "2015-01-13",
      "enrollment": 0,
      "sponsor": "Exelixis"
    },
    {
      "nct_id": "NCT01441947",
      "title": "Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Breast Cancer",
      "start_date": "2011-10",
      "completion_date": "2019-08-09",
      "enrollment": 0,
      "sponsor": "Massachusetts General Hospital"
    },
    {
      "nct_id": "NCT02721459",
      "title": "XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Melanoma, Skin Cancer",
      "start_date": "2016-09-07",
      "completion_date": "2026-11",
      "enrollment": 0,
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 25,
      "PHASE3": 4,
      "PHASE1, PHASE2": 1,
      "PHASE1": 18,
      "NA": 1,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "TERMINATED": 7,
      "RECRUITING": 15,
      "COMPLETED": 14,
      "ACTIVE_NOT_RECRUITING": 10,
      "NOT_YET_RECRUITING": 3,
      "WITHDRAWN": 1
    },
    "active_trials": 25,
    "completed_trials": 14,
    "conditions": [
      "Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma",
      "Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma",
      "Advanced Solid Tumor",
      "Aggressive Variant Prostate Carcinoma",
      "Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors",
      "Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct",
      "Brain Metastases, Renal Cell Carcinoma",
      "Breast Cancer",
      "Cancer",
      "Cancer, Non-small-cell Lung Cancer, Breast Cancer",
      "Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma",
      "Carcinoma, Non-Small-Cell Lung",
      "Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone",
      "Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma",
      "Colorectal Cancer",
      "Gastric Adenocarcinoma, GastroEsophageal Cancer",
      "Head and Neck Squamous Cell Carcinoma",
      "Healthy, Hepatic Impairment",
      "Hepatic Impairment, Moderate Hepatic Impairment",
      "Hepatocellular Carcinoma",
      "High Grade Neuroendocrine Neoplasms",
      "Locally Advanced Hepatocellular Carcinoma",
      "Locally Advanced Renal Cell Carcinoma",
      "Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC",
      "Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma",
      "Melanoma",
      "Melanoma, Skin Cancer",
      "Meningioma",
      "Merkel Cell Carcinoma, Skin Cancer",
      "Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma",
      "Metastatic Hormone Refractory Prostate Cancer",
      "Metastatic Renal Cell Carcinoma Treated With Cabozantinib",
      "Metastatic Soft-tissue Sarcoma",
      "Neoadjuvant Treatment, Thyroid Cancer",
      "Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer",
      "Neuroblastoma, Sarcoma",
      "Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)",
      "Pancreatic Adenocarcinoma Metastatic",
      "Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Follicular Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IVA Thyroid Gland Follicular Carcinoma, Stage IVA Thyroid Gland Papillary Carcinoma, Stage IVB Thyroid Gland Follicular Carcinoma, Stage IVB Thyroid Gland Papillary Carcinoma, Stage IVC Thyroid Gland Follicular Carcinoma, Stage IVC Thyroid Gland Papillary Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Oncocytic Follicular Carcinoma",
      "Prostate Cancer",
      "Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms",
      "Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms",
      "RCC, Renal Cell Carcinoma",
      "Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia",
      "Renal Cell Carcinoma",
      "Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities",
      "Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor",
      "Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:35.114700",
    "search_query": "Exelixis",
    "url": "https://clinicaltrials.gov/search?term=Exelixis"
  }
}